

AMENDMENTS TO THE CLAIMS:

1. – 30. (Canceled)

31. (**Currently Amended**) A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition comprising:
a cell expressing a cytokine from a recombinant polynucleotide,
wherein the cytokine **comprises a heterologous transmembrane region and** is stably associated in the cell outer membrane ,
and wherein the cell has been inactivated to prevent proliferation.

32. (Previously presented) The method of claim 31, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- α , and M-CSF.

33. (Previously presented) The method of claim 31, wherein the cell is a cancer cell.

34. (Previously presented) The method of claim 31, wherein the cell is from a tumor of the same tissue type as a tumor in the subject.

35. (Previously presented) The method of claim 34, wherein the tumor is an ovarian cancer or a brain cancer.

36. (Previously presented) The method of claim 31, wherein the cell is allogeneic to the subject.

37. (Previously presented) The method of claim 31, wherein the cell is histocompatibly identical to the subject.

38. (**Currently Amended**) The method of ~~claim 31~~ **any of claims 31, 61, or 62**, wherein the composition further comprises a tumor-associated antigen, and wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.

39. (Previously presented) The method of claim 38, wherein the tumor-associated antigen is obtained from a cell autologous to the subject.
40. (Previously presented) The method of claim 38, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.
41. (Previously presented) The method of claim 38, wherein the composition comprises a combination of:
 - a) the cell expressing the membrane-associated cytokine; and
 - b) a tumor cell autologous to the subject;wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.
42. (Previously presented) The method of claim 41, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the subject.
43. (Previously presented) The method of claim 41, wherein the tumor cell is a glioma, a glioblastoma, a gliosarcoma, an astrocytoma, or an ovarian cancer cell.
44. (Previously presented) The method of claim 41, wherein the tumor cell has been inactivated by irradiation.
45. (Previously presented) The method of claim 31, wherein the cell expressing the membrane-associated cytokine has been inactivated by irradiation.
46. (Previously presented) The method of claim 31, wherein the cell produces a secreted cytokine in addition to the cytokine stably associated in the outer membrane.
47. (Previously presented) The method of claim 31, wherein a majority of the cytokine produced by the cell is present on the outer membrane of the cell.

48. (Cancelled).
49. (Previously presented) The method of claim 31, wherein the composition comprises at least two cells, each of which has been genetically altered to produce a different cytokine at an elevated level, or is the progeny of such a cell, and wherein each cytokine is stably associated in the outer membrane of the cell.
50. (Cancelled)
51. (Previously presented) The method of claim 31, wherein the cell is a human cell.
52. (Canceled)
53. **(Currently Amended)** The method of ~~claim 31~~ claim 61 or claim 62, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.
54. **(Currently Amended)** The method of claim 31, wherein the cell in the composition has been transduced in vitro with a retroviral expression vector, or is the progeny of such a cell.
55. (Previously presented) The method of claim 31, which is a method for priming an anti-tumor immune response.
56. (Previously presented) The method of claim 31, which is a method for boosting or maintaining an anti-tumor immune response.
57. (Previously presented) The method of claim 31, which is a method for treating a neoplastic disease.
58. (Previously presented) The method of claim 31, further comprising providing the cytokine expressing cell that is present in the composition.

59. (Previously presented) The method of claim 38, further comprising providing the tumor associated antigen that is present in the composition.
60. (Currently Amended) The method of claim 31, further comprising preparing the composition by transducing a cancer cell *in vitro* with an expression vector encoding the membrane-associated cytokine.
61. (Currently Amended) ~~The method of claim 31, wherein the cytokine is IL-4~~
A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition comprising a cell expressing an IL-4 from a recombinant polynucleotide,
wherein the IL-4 is stably associated in the cell outer membrane,
and wherein the cell has been inactivated to prevent proliferation.
62. (Currently Amended) ~~The method of claim 31, wherein the cytokine is GM-CSF~~
A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition comprising a cell expressing a GM-CSF from a recombinant polynucleotide,
wherein the GM-CSF is stably associated in the cell outer membrane,
and wherein the cell has been inactivated to prevent proliferation.
63. (Previously presented) The method of claim 31, wherein the cytokine is M-CSF
- 64 to 79. (Cancelled)